C

Castle Biosciences, Inc. Tech Stack

Molecular diagnostics for melanoma, skin cancer, and Barrett's esophagus

Biotechnology Research Friendswood, Texas 501–1,000 employees Founded 2008 Public Company

Castle Biosciences runs a publicly traded diagnostics company (Nasdaq: CSTL) built around proprietary gene expression profile tests for dermatologic oncology and esophageal disease. The tech stack is enterprise Microsoft (Azure, 365, PowerShell, Active Directory) — typical for a clinical-stage biotech — but the hiring and pain-point mix reveals the real operational bottleneck: payer reimbursement. Research and healthcare roles dominate the open headcount, paired with urgent internal work on payer enrollment, claims processing, and billing compliance, signaling that commercial adoption hinges on solving revenue-cycle friction rather than test development.

Tech Stack 12 technologies

Core StackPython AWS Active Directory Azure Excel Word PowerPoint SharePoint Outlook PowerShell Microsoft 365 Microsoft Office

What Castle Biosciences, Inc. Is Building

◆Challenges

High volume claims processing
Maintaining up-to-date payer information
Ensuring compliance with payer guidelines
Medical record compliance
Claim denial resolution
Ensuring quality of outsourced billing work
Managing outsourced vendor performance
Streamlining payer enrollment
Reducing billing errors
Improving revenue cycle compliance

▲Active Projects

Nationwide payer enrollment and credentialing
Workflow design and regression testing
System configuration and maintenance
Crf development
Clinical study design

Hiring Activity

Steady35 roles · 15 in 30d

Department

Research

12

Healthcare

7

Finance

5

Ops

3

Marketing

2

Support

2

Engineering

1

Seniority

Mid

20

Junior

8

Manager

2

Lead

1

Senior

1

Company intelligence

Find more companies like Castle Biosciences, Inc. by tech stack, pain points and active projects

Get started free

About Castle Biosciences, Inc.

Castle Biosciences is a Nasdaq-listed diagnostics company headquartered in Friendswood, Texas, founded in 2008. The company commercializes five proprietary tests across three clinical areas: cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-SCC, MyPath® Melanoma), uveal melanoma (DecisionDx®-UM, which is the standard of care in uveal melanoma staging), and Barrett's esophagus (TissueCypher® Barrett's Esophagus). Each test uses gene expression profiling to guide treatment decisions and predict patient risk. The company employs 501–1,000 people and operates across the United States. Current operational focus includes nationwide payer credentialing, workflow design, clinical study execution, and managing the claims-to-payment pipeline.

HeadquartersFriendswood, Texas

Company Size501–1,000 employees

Founded2008

Hiring MarketsUnited States

Frequently Asked Questions

What are Castle Biosciences' main diagnostic tests?

Five tests: DecisionDx®-Melanoma and DecisionDx®-SCC (cutaneous melanoma and squamous cell carcinoma risk), MyPath® Melanoma (lesion characterization), DecisionDx®-UM (uveal melanoma staging), and TissueCypher® Barrett's Esophagus (esophageal cancer risk prediction).

Where is Castle Biosciences headquartered?

Friendswood, Texas. The company is publicly traded on Nasdaq under ticker CSTL and was founded in 2008.

What is Castle Biosciences working on operationally?

Nationwide payer enrollment and credentialing, workflow design, regression testing, clinical study design, and CRF development. Pain points center on high-volume claims processing, maintaining payer information, and reducing billing errors.